

A large, modern laboratory workstation with a grey and white color scheme. The top section is labeled 'AMGEL' and 'EFEVRE TECH'. It features a control panel on the left and a large window showing internal components. The bottom section has a window showing a rack of test tubes or vials. The background is a blurred laboratory setting with people in white coats.

AMGEL

EFEVRE TECH

Transforming Life Science Laboratories

Empowering researchers
to create reliable,
reproducible medical
breakthroughs with
innovative technology.



EFEVRE TECH

Inventing Technologies

Seed Investor Presentation

PROBLEM

**Life-science
researchers
struggle with
non-reproducible
results.**



Reproducibility crisis

✘ PROBLEMS


 **70% Non-repeatable results**

 **Long time to market for new drugs**
(10-15 yrs avg)

 **Inadequate lab automation solutions**

➔ OUTCOMES

 \$28 Billion loss annually

 Needed drugs not available with insufficient data based on the research

 **Untapped market for everyday benchwork**

TREND

Life-science instrumentation market is growing


OPPORTUNITY


\$107B


Life sciences market in 2030

GROWTH DRIVERS

 Increasing Funding in Life Sciences and Drug discovery

 Government Initiatives to Strengthen laboratories for pandemic preparedness


 Global increase in DNA analytical methods



Transforming life science research

Empowering researchers for reliable, reproducible medical breakthroughs

Efevre Tech has developed **AMGEL 247 Pro**, an autonomous lab automation robot for **everyday life science research**.



- **Versatile:** Automate endless procedures
- The only solution to offer full **autonomy and 24/7 automation**
- **AI powered software** develop any automated protocol and utilize the AI capabilities
- **Modular:** Add components at different stages
- **Compact:** Full lab in 3 cubic meters

Eliminate errors, increase productivity, save costs - responding to the needs of everyday life science laboratories



Eliminate Errors

Minimize human handling variabilities and inconsistencies to ensure reproducible results



Versatile Processes

AI powered Software for freedom to develop any automated protocol, easily changed between procedures



Increased Productivity

Full autonomy for 24-7 operation without human supervision



Affordable and Cost Effective

One AMGEL device replaces several expensive workstations, fit in 3²sq, making it an affordable solutions to the laboratories

From idea to pilot to MVP with full readiness to capture the market

FOUNDED Q1 2018

☑ Completed

- ☑ Established in 2018
- ☑ Pilot completed in 2020
- ☑ MVP sold in 2021
- ☑ Acquired USA provisional patent
- ☑ Filed European Utility patent

Q1 2023

⚙ In Progress

- ⚙ Raising seed funding
- ⚙ Finalize AMGEL 247 Pro technology
- ⚙ Developing distribution networks
- ⚙ Obtaining CE certificate
- ⚙ Expanding sales in EU
- ⚙ Execute POC studies

Q3 2023 - Q2 2024

➡ Planned

- ➡ Complete R&D by Q4 2023
- ➡ Go-To-Market in Q2 2024
- ➡ Expand to US in 2025
- ➡ IPO in 2029

Operating on a B2B model with innovative lab automation technology and versatile solutions.

CORE PRODUCT

STARTING FROM

€375,000/unit


 AMGEL 247 Pro

- » All the features and benefits of the AMGEL device
- » Direct selling and distributors network
- » Special customization at additional costs

SECONDARY SERVICE

STARTING FROM

€46,000/yr/unit


 Maintenance & Consumables & Data

- » Regular maintenance
- » Supply of consumables
- » Customization and data services
- » Software maintenance

HOW IT WORKS

AMGEL 247PRO is built with the versatile needs of the everyday life science researchers in mind

From the liquid handlers, to the robotic arm and the GPT4 powered, easy-to-operating software, **AMGEL 247PRO** allows for various procedures to run simultaneously, without human intervention.



Utility Patents submitted protect how AMGEL247PRO operates



Leveraging on deep understanding of the needs of life science everyday research labs to provide the needed solution

Full Autonomy



Biosero

BioNex Solutions

Thermo Scientific

Limited Versatility

High Versatility

Agilent Technologies

Hamilton Robotics

Tecan Group

Roche

Manual Labor

LEADERSHIP OVER COMPETITION

Costs

40%

less than leading automation manufacturers

X10

Higher productivity per machine

OPPORTUNITY

Tapping a global \$107B market by 2030.

Launch

🌐 ANNUAL MARKET OPPORTUNITY

88,000

Life Science Laboratories

TOTAL
AVAILABLE
MARKET

8.800

Life science laboratories

10% of TAM, untapped everyday life science research market

SERVICEABLE
AVAILABLE
MARKET

\$660M

**Automation
demanding Labs**

1% of TAM, targeting 10% of non-automatic labs

SERVICEABLE
OBTAINABLE
MARKET

Expansion

ADDITIONAL OPPORTUNITIES

\$10B/yr

🧪 Biotechnology

\$5B/yr

🧬 Epidemiology

\$20B/yr

💊 Pharmaceutical

Driving growth with strategic partnerships in leading markets

6 machines



Secure seed round funding

Partner with leading research facilities

Establish sales in EU markets

48 machines



Establish distribution networks

Increase production capacity

Secure Round A funding

400 machines



Optimize assembly facilities

Enter US market

Expand product offerings

Prepare for IPO

TEAM

Led by a dedicated team with extensive expertise in life-science and engineering



Dimitris Kyriakou
Founder & CEO

PH.D in Molecular Biology

Visionary - Transforming life science research

Expertise in biotechnology and basic research.



Constantinos Odysseos
Co-founder & CTO

BSc in Mechanical Engineering

Specialises in Industrial Design & Manufacturing

R&D



Marios Konstantinou
Backend SW Development



Nektarios Taliadouros
Refrigeration Expert



Filippou Onisiforou
Electrical Automation



Antonios Inglezakis
Electronics & Software



Andreas Georgiou
Frontend Engineer


Marketing & Sales



Rafaella Hadjicosti
Branding, Marketing, PR



Iro Pelekanou
Sales and Biz Dev



Andrea Plastira
Sales

Financials and Administration



Soterios Pavlides
Business Administration




Kyprianos Photiou
Financials

Raising 2.5M euros to reach 20M euros in sales by end of 2026


2.5M euros

24 Months of Runway



INVESTMENT WILL ENABLE...

- ✓ **Expanding R&D capabilities** to finalize the AMGEL 247 Pro and conduct POC studies with leading research facilities
- ✓ **Investing in marketing and sales** efforts to solidify our position in the life science and laboratory equipment market
- ✓ **Scaling operations and distribution networks** to reach 400 machines sold/leased per year by 2028 and 3,000 machines per year by 2033



EFEVRE TECH

Inventing Technologies

WHY NOW

Only 8% of the \$107B market is automated

Seed round to complete R&D and PoC
with leading research facility



Dimitris Kyriakou

Founder & CEO

dkyriakou@efevretech.com